Results 61 to 70 of about 5,281 (192)

The Troll Is Weakened but Not yet Defeated: An Update on Cytomegalovirus Management in Transplantation From the International CMV Symposium 2025

Transplant Infectious Disease, Volume 28, Issue 3, May/June 2026.
This review synthesizes discussions from the 2025 International CMV Symposium on translating three recently updated international guidelines into clinical practice across solid organ and hematopoietic stem cell transplantation, highlighting advances in risk‐stratified prevention, emerging therapies, immune monitoring, and persistent implementation ...
Camille N. Kotton, Martina Sester, Julian Torre‐Cisneros, The International CMV Symposium Faculty   +3 more
wiley   +1 more source

Development and evidence for efficacy of CMV glycoprotein B vaccine with MF59 adjuvant [PDF]

Journal of Clinical Virology, 2009
A vaccine comprised of recombinant cytomegalovirus (CMV) envelope glycoprotein B (gB) with MF59 adjuvant developed in the 1990s recently was recently found to have efficacy for prevention of CMV infection in a phase 2 clinical trial in young mothers.
openaire   +2 more sources

MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18–60 years of age) with chronic diseases who are at risk of post-influenza complications

, 2007
The immunogenicity and reactogenicity of two influenza vaccines were evaluated in a randomised, double-blind trial in north-east Italy during winter 2005-2006. Of 238 adult subjects (18-60 years of age) with underlying chronic diseases, 120 received MF59-
TRIVELLO, RENZO, A. M. Carraro, FLOREANI, ANNAROSA, BALDO, VINCENZO, BALDOVIN, TATJANA, Family Medicine Group of Pianiga   +5 more
core   +1 more source

The Protective Effects of the A/ZJU01/ PR8/2013 Split H7N9 Avian Influenza Vaccine Against Highly Pathogenic H7N9 in BALB/c Mice

Cellular Physiology and Biochemistry, 2018
Background/Aims: Since the first case of novel H7N9 infection was reported, China has experienced five epidemics of H7N9. During the fifth wave, a highly pathogenic H7N9 strain emerged. In order to assess whether the H7N9 vaccine based on A/Zhejiang/DTID-
Xiao-Xin Wu, Xi-Long Deng, Dong-Shan Yu, Wei Yao, Hui-Lin Ou, Tian-Hao Weng, Chen-Yu Hu, Feng-Yu Hu, Nan-Ping Wu, Hangping Yao, Fu-Chun Zhang, Lan-Juan Li   +11 more
doaj   +1 more source

Serum neutralizing activity against HIV strains in animals immunized in the MF59 study.

, 2019
Serum neutralizing activity against HIV strains in animals immunized in the MF59 study.
Melvin N. Doster (6694943), Ruth M. Ruprecht (8072033), Josh Kramer (1517812), Luca Schifanella (6694940), Celia C. LaBranche (172138), Karin Loré (8072030), Xiaoying Shen (164029), David J. Venzon (7478117), Sanjay Phogat (3780025), Frank Liang (6858878), Hung V. Trinh (5146997), Michelle Metrinko (6858884), Massimiliano Bissa (4811226), David C. Montefiori (7392644), Monica Vaccari (782730), Dallas R. Brown (6694934), Mangala Rao (147350), Galit Alter (91383), Robyn Washington-Parks (8072024), Susan W. Barnett (8072021), Georgia D. Tomaras (7163792), Matthew Breed (6858886), Namal P. M. Liyanage (8072027), Ranajit Pal (782728), William Magnanelli (6858883), Veronica Galli (6858876), Genoveffa Franchini (384425)   +26 more
core   +1 more source

Alum adjuvant is more effective than MF59 at prompting early germinal center formation in response to peptide-protein conjugates and enhancing efficacy of a vaccine against opioid use disorders

Human Vaccines & Immunotherapeutics, 2019
Opioid use disorders (OUD) and fatal overdoses are a national emergency in the United States. Therapeutic vaccines offer a promising strategy to treat OUD and reduce the incidence of overdose.
Christine Robinson, Carly Baehr, Shirdi E. Schmiel, Claudia Accetturo, Daniel L. Mueller, Marco Pravetoni   +5 more
doaj   +1 more source

Development of a Novel Polyleucine‐Based Immunopotentiator for Subunit Vaccines Against Group A Streptococcus

Small, Volume 22, Issue 22, 17 April 2026.
Self‐assembling amphiphilic peptide L15K6 is used as a novel immunoadjuvant for the development of a Group A Streptococcus vaccine. Robust antigen‐specific IgG responses are generated and manage to kill isolated strains of Group A Streptococcus. Cellular and bulk RNA sequencing data reveals that L15K6 regulates immune responses potentially through TLR ...
Lantian Lu, Jazmina L. Gonzalez Cruz, Rabina Giri, Yuexiao Zhang, Sahra Bashiri, Leslie C. Domínguez Cadena, Shuhang Li, Zeinab G. Khalil, Waleed M. Hussein, Jingwen Wang, Jolynn Kiong, Xuehan Lu, Jiahui Zhang, Miao Lu, Wenbin Huang, Wei Yang Kong, Ummey Jannatun Nahar, Prashamsa Koirala, Zhong Guo, Patricia Walden, Antje Blumenthal, Jakob Begun, Kirill Alexandrov, Istvan Toth, Rachel J. Stephenson, Mariusz Skwarczynski   +25 more
wiley   +1 more source

Squalene emulsion-based vaccine adjuvants stimulate CD8 T cell, but not antibody responses, through a RIPK3-dependent pathway

eLife, 2020
The squalene-based oil-in-water emulsion (SE) vaccine adjuvant MF59 has been administered to more than 100 million people in more than 30 countries, in both seasonal and pandemic influenza vaccines.
Eui Ho Kim, Matthew C Woodruff, Lilit Grigoryan, Barbara Maier, Song Hee Lee, Pratyusha Mandal, Mario Cortese, Muktha S Natrajan, Rajesh Ravindran, Huailiang Ma, Miriam Merad, Alexander D Gitlin, Edward S Mocarski, Joshy Jacob, Bali Pulendran   +14 more
doaj   +1 more source

A Prussian Blue Nanozyme‐Adjuvanted Vaccine Presenting Phosphocholine Antigens for Induction of Immunotolerance in Inflammatory Bowel Disease

Advanced Science, Volume 13, Issue 16, 18 March 2026.
This study developed a novel nano‐vaccine (Ferritin‐PC@PBNZs) comprising a ferritin‐based scaffold for the multivalent display of phosphorylcholine (PC) antigens, integrated with Prussian blue nanozymes (PBNZs) as a potent adjuvant. By leveraging the ferritin carrier for high‐density and ordered antigen display, the nano‐vaccine significantly augments ...
Jingyi Sheng, Yubo Huang, Xinyue Li, Yin Liu, Yuehuang Wu, Yuxin Zhang, Ning Gu   +6 more
wiley   +1 more source

Immunogenicity and safety of MF59-adjuvanted quadrivalent influenza vaccine versus standard and alternate B strain MF59-adjuvanted trivalent influenza vaccines in older adults

Vaccine, 2020
Evaluate whether adjuvanted quadrivalent influenza vaccine (aQIV) elicits a noninferior immune response compared with a licensed adjuvanted trivalent influenza vaccine (aTIV-1; Fluad™) and aTIV-2 containing an alternate B strain, examine whether aQIV had immunological superiority for the B strain absent from aTIV comparators, and evaluate ...
Brandon, Essink, Carlos, Fierro, Jeffrey, Rosen, Amparo L, Figueroa, Bin, Zhang, Carole, Verhoeven, Jonathan, Edelman, Igor, Smolenov   +7 more
openaire   +2 more sources